This invention relates to pharmaceutical combinations of a cholesteryl
ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable
salt thereof; and an antihypertensive agent or a pharmaceutically
acceptable salt thereof, optionally in combination with an HMG CoA
reductase inhibitor or a pharmaceutically acceptable salt thereof, kits
containing such combinations and methods of using such combinations to
treat subjects suffering from atherosclerosis, peripheral vascular
disease, dyslipidemia, hyperbetaliproteinemia, hypoalphalipoproteinemia,
hypercholesterolemia, hypertriglyceridemia,
familial-hypercholesterolemia, cardiovascular disorders, angina,
ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion
injury, angioplastic restenosis, hypertension, vascular complications of
diabetes, obesity or endotoxemia in a mammal (including a human being
either male or female).